Dataset Information

IL1? Antagonizes IL1? and Promotes Adaptive Immune Rejection of Malignant Tumors.

ABSTRACT: We assessed the contribution of IL1 signaling molecules to malignant tumor growth using IL1?-/-, IL1?-/-, and IL1R1-/- mice. Tumors grew progressively in IL1R-/- and IL1?-/- mice but were often absent in IL1?-/- mice. This was observed whether tumors were implanted intradermally or injected intravenously and was true across multiple distinct tumor lineages. Antibodies to IL1? prevented tumor growth in wild-type (WT) mice but not in IL1R1-/- or IL1?-/- mice. Antibodies to IL1? promoted tumor growth in IL1?-/- mice and reversed the tumor-suppressive effect of anti-IL1? in WT mice. Depletion of CD8+ T cells and blockade of lymphocyte mobilization abrogated the IL1?-/- tumor suppressive effect, as did crossing IL1?-/- mice to SCID or Rag1-/- mice. Finally, blockade of IL1? synergized with blockade of PD-1 to inhibit tumor growth in WT mice. These results suggest that IL1? promotes tumor growth, whereas IL1? inhibits tumor growth by enhancing T-cell-mediated antitumor immunity.

SUBMITTER: Tian T

PROVIDER: S-EPMC7596693 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

IL1α Antagonizes IL1β and Promotes Adaptive Immune Rejection of Malignant Tumors.

Tian Tian T Lofftus Serena S Pan Youdong Y Stingley Claire A CA King Sandra L SL Zhao Jingxia J Pan Timothy Y TY Lock Rebecca R Marglous Jacob W JW Liu Kevin K Widlund Hans R HR Fuhlbrigge Robert C RC Cichowski Karen K Kupper Thomas S TS

Cancer immunology research 20200311 5

We assessed the contribution of IL1 signaling molecules to malignant tumor growth using IL1β-/-, IL1α-/-, and IL1R1-/- mice. Tumors grew progressively in IL1R-/- and IL1α-/- mice but were often absent in IL1β-/- mice. This was observed whether tumors were implanted intradermally or injected intravenously and was true across multiple distinct tumor lineages. Antibodies to IL1β prevented tumor growth in wild-type (WT) mice but not i ...[more]

PMID: 32161110

Similar Datasets

Project description:Exposure to asbestos is causally associated with the development of malignant mesothelioma, a cancer of cells lining the internal body cavities. Malignant mesothelioma is an aggressive cancer resistant to all current therapies. Once inhaled or ingested, asbestos causes inflammation in and around tissues that come in contact with these carcinogenic fibers. Recent studies suggest that inflammation is a major contributing factor in the development of many types of cancer, including malignant mesothelioma. The NALP3/NLRP3 inflammasome, including the component ASC, is thought to be an important mediator of inflammation in cells that sense extracellular insults, such as asbestos, and activate a signaling cascade resulting in release of mature IL1β and recruitment of inflammatory cells. To determine if inflammasome-mediated inflammation contributes to asbestos-induced malignant mesothelioma, we chronically exposed Asc-deficient mice and wild-type littermates to asbestos and evaluated differences in tumor incidence and latency. The Asc-deficient mice showed significantly delayed tumor onset and reduced malignant mesothelioma incidence compared with wild-type animals. We also tested whether inflammation-related release of IL1β contributes to tumor development in an accelerated mouse model of asbestos-induced malignant mesothelioma. Nf2(+/-);Cdkn2a(+/-) mice exposed to asbestos in the presence of anakinra, an IL1 receptor (IL1R) antagonist, showed a marked delay in the median time of malignant mesothelioma onset compared with similarly exposed mice given vehicle control (33.1 weeks vs. 22.6 weeks, respectively). Collectively, these studies provide evidence for a link between inflammation-related IL1β/IL1R signaling and the development of asbestos-induced malignant mesothelioma. Furthermore, these findings provide rationale for chemoprevention strategies targeting IL1β/IL1R signaling in high-risk, asbestos-exposed populations. Cancer Prev Res; 9(5); 406-14. ©2016 AACR.

Project description:Repeated mechanical stress causes injuries in the adult skeletal muscle that need to be repaired. Although muscle regeneration is a highly efficient process, it fails in some pathological conditions, compromising tissue functionality. This may be caused by aberrant cell-cell communication, resulting in the deposition of fibrotic and adipose infiltrates. Here, we investigate in vivo changes in the profile of skeletal muscle secretome during the regeneration process to suggest new targetable regulatory circuits whose failure may lead to tissue degeneration in pathological conditions. We describe the kinetic variation of expression levels of 76 secreted proteins during the regeneration process. In addition, we profile the gene expression of immune cells, endothelial cells, satellite cells, and fibro-adipogenic progenitors. This analysis allowed us to annotate each cell-type with the cytokines and receptors they have the potential to synthetize, thus making it possible to draw a cell-cell interaction map. We next selected 12 cytokines whose receptors are expressed in FAPs and tested their ability to modulate FAP adipogenesis and proliferation. We observed that IL1α and IL1β potently inhibit FAP adipogenesis, while EGF and BTC notably promote FAP proliferation. In addition, we characterized the cross-talk mediated by extracellular vesicles (EVs). We first monitored the modulation of muscle EV cargo during tissue regeneration. Using a single-vesicle flow cytometry approach, we observed that EVs differentially affect the uptake of RNA and proteins into their lumen. We also investigated the EV capability to interact with SCs and FAPs and to modulate their proliferation and differentiation. We conclude that both cytokines and EVs secreted during muscle regeneration have the potential to modulate adipogenic differentiation of FAPs. The results of our approach provide a system-wide picture of mechanisms that control cell fate during the regeneration process in the muscle niche.

Dataset Information

IL1? Antagonizes IL1? and Promotes Adaptive Immune Rejection of Malignant Tumors.

Publications

IL1α Antagonizes IL1β and Promotes Adaptive Immune Rejection of Malignant Tumors.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets